Tiziana Life Sciences (TLSA) News Today $1.50 +0.02 (+1.35%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's DiseaseMay 15, 2025 | finance.yahoo.comTiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study showsMay 15, 2025 | proactiveinvestors.comAnalyzing Tiziana Life Sciences (NASDAQ:TLSA) and MacroGenics (NASDAQ:MGNX)May 13, 2025 | americanbankingnews.comTiziana Life Sciences reports purchase of shares by chairmanMay 12, 2025 | msn.comTiziana Life Sciences Announces Purchase of Shares by ChairmanMay 12, 2025 | globenewswire.comTiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumabMay 9, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal ForalumabMay 9, 2025 | globenewswire.comTiziana shares surge 21% on promising multiple sclerosis dataMay 6, 2025 | proactiveinvestors.comTiziana reports encouraging results for nasal MS drug in early studyMay 6, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple SclerosisMay 6, 2025 | globenewswire.comTiziana Life Sciences (NASDAQ:TLSA) Shares Up 5.6% - Here's What HappenedTiziana Life Sciences (NASDAQ:TLSA) Trading 5.6% Higher - Still a Buy?April 24, 2025 | marketbeat.comTiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of MassachusettsApril 23, 2025 | proactiveinvestors.comTiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis TrialApril 23, 2025 | globenewswire.comTiziana Life announces dosing at JHU, part of Phase 2 trial of foralumabApril 3, 2025 | markets.businessinsider.comTiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns HopkinsApril 2, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical TrialApril 2, 2025 | globenewswire.comShort Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Rises By 42.5%Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 808,600 shares, a growth of 42.5% from the February 28th total of 567,600 shares. Approximately 1.1% of the company's stock are sold short. Based on an average trading volume of 979,300 shares, the short-interest ratio is currently 0.8 days.March 31, 2025 | marketbeat.comTiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMSMarch 25, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis TrialMarch 25, 2025 | globenewswire.comTiziana Life Sciences to Present at the 37th Annual Roth ConferenceMarch 17, 2025 | globenewswire.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Down 39.2% in FebruaryTiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 567,600 shares, a drop of 39.2% from the February 13th total of 934,300 shares. Approximately 0.8% of the shares of the stock are sold short. Based on an average trading volume of 955,300 shares, the short-interest ratio is presently 0.6 days.March 16, 2025 | marketbeat.comTiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price RuleMarch 14, 2025 | globenewswire.comTiziana: Foralumab Drug Development Presses On With Additional EAP EnrollmentMarch 6, 2025 | seekingalpha.comTiziana submits FDA investigational new drug applicationMarch 4, 2025 | proactiveinvestors.comTiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical TrialMarch 4, 2025 | globenewswire.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Drop in Short InterestTiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) saw a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 934,300 shares, a decrease of 23.4% from the January 31st total of 1,220,000 shares. Based on an average daily volume of 690,700 shares, the days-to-cover ratio is presently 1.4 days. Currently, 1.3% of the company's shares are sold short.March 4, 2025 | marketbeat.comTiziana Life Sciences nasal anti-CD3 therapy shows promise in treating traumatic brain injury, study revealsFebruary 27, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain InjuryFebruary 27, 2025 | globenewswire.comTiziana Life Sciences expects to complete Long Covid study in Q2February 25, 2025 | markets.businessinsider.comTiziana Life Sciences nearing completion of long COVID study on foralumabFebruary 25, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Long Covid Study to Complete in Second QuarterFebruary 25, 2025 | globenewswire.comTiziana Life Sciences advances foralumab towards commercialization with key manufacturing partnershipFebruary 21, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLCFebruary 21, 2025 | globenewswire.comTiziana Life Sciences doses additional four patients in multiple sclerosis trialFebruary 18, 2025 | markets.businessinsider.comTiziana Life Sciences announces dosing of additional patients in MS Expanded Access ProgramFebruary 18, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access ProgramFebruary 18, 2025 | globenewswire.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Growth in Short InterestTiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,220,000 shares, a growth of 128.0% from the January 15th total of 535,000 shares. Currently, 1.7% of the shares of the stock are sold short. Based on an average trading volume of 595,600 shares, the short-interest ratio is currently 2.0 days.February 13, 2025 | marketbeat.comTiziana Life Sciences says foralumab shows promise in Alzheimer's treatmentFebruary 11, 2025 | proactiveinvestors.comTiziana announces TV interview with AD patient dosed with foralumabFebruary 11, 2025 | markets.businessinsider.comTiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s DiseaseFebruary 11, 2025 | markets.businessinsider.comTiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's DiseaseFebruary 11, 2025 | globenewswire.comShort Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Drops By 21.4%Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) saw a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 535,000 shares, a decrease of 21.4% from the December 31st total of 680,800 shares. Currently, 0.8% of the company's shares are sold short. Based on an average daily trading volume, of 636,800 shares, the days-to-cover ratio is presently 0.8 days.January 31, 2025 | marketbeat.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Growth in Short InterestTiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 680,800 shares, a growth of 300.2% from the December 31st total of 170,100 shares. Based on an average daily volume of 348,300 shares, the short-interest ratio is presently 2.0 days. Approximately 1.0% of the company's shares are short sold.January 28, 2025 | marketbeat.comTiziana Life Sciences reports promising preclinical results for nasal anti-CD3 in spinal cord injuryJanuary 23, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3January 23, 2025 | globenewswire.comTiziana Life Sciences not to engage in capital raising activities for the immediate futureJanuary 23, 2025 | globenewswire.comTiziana Life Sciences identifies new immune biomarkers in MS patients treated with foralumabJanuary 22, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal ForalumabJanuary 22, 2025 | globenewswire.comTiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3January 10, 2025 | markets.businessinsider.comTiziana Life Sciences' foralumab reduces side effects of discontinuing GLP-1 agonistsJanuary 10, 2025 | proactiveinvestors.com Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address TLSA Media Mentions By Week TLSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TLSA News Sentiment▼0.330.65▲Average Medical News Sentiment TLSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TLSA Articles This Week▼21▲TLSA Articles Average Week Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RCKT News Today AVBP News Today DAWN News Today TRVI News Today IMTX News Today SION News Today EOLS News Today VIR News Today REPL News Today PHAR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TLSA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TLSA Stock Free TLSA Stock Alerts